Plain-English translation of NCT02348008 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial examined whether combining two medications — and — could help treat advanced kidney cancer more effectively. The study had two stages: first, researchers tested different dose combinations to find the safest level, and then they studied how well this medication combination worked in patients with newly diagnosed advanced kidney cancer.
Advanced kidney cancer is difficult to treat, and many patients do not respond well to existing therapies. This trial was designed to see whether combining these two medications — which work in different ways to fight cancer — could offer better results than either treatment alone.
Participants in the first stage received intravenous infusions of both medications on day one of each 21-day cycle, with doses tested at different levels to determine safety. Those in the second stage received the safest dose combination determined from the first stage and continued treatment every 21 days until their disease progressed, they experienced unacceptable side effects, or they chose to stop. All participants were followed for up to 24 months total to monitor their progress and any side effects from treatment.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States